ERBB2 and breast carcinoma: We investigated the association between isoform expressions and sensitivity to lapatinib, a dual tyrosine kinase inhibitor, which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways, and is a FDA-approved drug for breast cancer.